ArticleFrontiers in immunology2026
Waning of vaccine-induced measles antibodies and population immunity gaps in the post-elimination era: a multicenter seroepidemiological study in China.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite sustained high measles-containing vaccine (MCV) coverage, maintaining population immunity after measles elimination remains challenging. This study aimed to characterize measles antibody persistence, identify immunity gaps, and evaluate factors associated with seronegativity in China. Methods: A multicenter cross-sectional serological survey was conducted among 2,083 participants from Jiangsu Province and Xinjiang Uygur Autonomous Region during 2024-2025. Measles-specific IgG antibodies were measured using ELISA, with seropositivity defined as IgG ≥200 mIU/mL. Restricted cubic spline models were used to assess antibody kinetics after excluding individuals without documented vaccination, those sampled within one month after vaccination, and potential primary vaccine failures. Multivariable logistic regression and propensity score matching were performed to evaluate factors associated with seronegativity. Results: Overall measles IgG seropositivity was 84.59% (95% CI: 82.98-86.08%), with a GMT of 482.48 mIU/mL. Seropositivity varied significantly by region, ethnicity, age, and vaccination history. Antibody levels showed a non-linear decline with increasing time since vaccination, and each additional year since the last vaccination increased seronegativity risk (AOR = 1.11, 95% CI: 1.07-1.15). Children aged 8-17 months had the lowest seropositivity (28.13%), indicating a potential susceptibility window. Although migrants had higher seropositivity than permanent residents (93.04% vs. 83.90%), migration status was not independently associated with seronegativity after adjustment. Conclusions: High MCV coverage does not necessarily ensure sustained population immunity in the post-elimination era. Waning humoral immunity, delayed vaccination, and heterogeneous vaccination histories contribute to residual susceptibility, highlighting the need for immunity-based surveillance and targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.